Savara awarded innovation passport in united kingdom (uk) for molgramostim nebulizer solution (molgramostim), a novel investigational inhaled biologic

Austin, texas--(business wire)--savara inc. (nasdaq: svra), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced molgramostim has been awarded an innovation passport for the treatment of apap by the uk's medicines and healthcare products regulatory agency (mhra). innovation passport is the entry point to the ilap, a novel program aimed at accelerating the time to market and facilitating patient access to medicines in the uk. in 2019, molgramostim was
SVRA Ratings Summary
SVRA Quant Ranking